Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669469 | 0.83 | CYP2A6 (0.40) | CYP1A2POLBCA12CA2HSD17B10 | |
| SCHEMBL18258983 | 0.81 | CYP2A6 (0.39) | CYP1A2POLBCA12CA2HSD17B10 | |
| SCHEMBL2373478 | 0.81 | SMN1; SMN2 (0.46) | POLBCA12CA2HSD17B10KDM4E | |
| SCHEMBL646330 | 0.81 | ALDH1A1 (0.42) | CYP1A2POLBCA12CA2HSD17B10 | |
| SCHEMBL18957552 | 0.79 | KDM4E (0.38) | CYP1A2POLBCA12CA2HSD17B10 | |
| SCHEMBL8434859 | 0.79 | CYP2A6 (0.50) | CYP1A2HSD17B10KDM4EALDH1A1RAB9A | |
| SCHEMBL9614637 | 0.79 | ALDH1A1 (0.50) | CYP1A2CA12CA2HSD17B10KDM4E | |
| SCHEMBL668681 | 0.79 | MAPT (0.42) | CYP1A2MCL1ACMSDCA12CA2 | |
| SCHEMBL10877443 | 0.78 | CYP1A2 (0.43) | CYP1A2MCL1ACMSDPTPN22HSD17B10 | |
| SCHEMBL578393 | 0.77 | ALDH1A1 (0.39) | CYP1A2POLBCA12CA2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550510-B2 | Solid phase synthesis of arylretinamides | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-20040102650-A1 | Solid phase synthesis of arylretinamides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-05-27 | — | — | US | disclosed |
| US-6696606-B2 | REACTING HEXACHLOROACETONE WITH TRIPHENYLPHOSPHINE; CHLORINATION OF RETINOIC ACID; THEN AROMATIC AMINE; ANTICANCER AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2004-02-24 | — | — | US | disclosed |
| US-20030105164-A1 | Solid phase synthesis of arylretinamides | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-05 | — | — | US | disclosed |
| WO-2003003987-A2 | SOLID PHASE SYNTHESIS OF ARYLRETINAMIDES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102650-A1 | Solid phase synthesis of arylretinamides | RARA, LRAT, NR2E3 | CYP1A2 2903/4885MCL1 507/4885ACMSD 2649/4885 |
| US-20030105164-A1 | Solid phase synthesis of arylretinamides | RARA, LRAT, NR2E3 | CYP1A2 2903/4885MCL1 507/4885ACMSD 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.